Publications by authors named "Bryan F Cox"

Claim this Profile
P
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models.
Lauren Cournoyer, Yujia Liu, David B Jaroch, Tom G Hullinger, Bryan F Cox

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pressure-Enabled Drug Delivery Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model.
David B Jaroch, Yujia Liu, Alexander Y Kim, Steven C Katz, Bryan F Cox

J Vasc Interv Radiol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model.
David B Jaroch, Yujia Liu, Alexander Y Kim, Steven C Katz, Bryan F Cox

J Vasc Interv Radiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases.
Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Bryan F Cox

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
Benedict A Capacio, Jayanth S Shankara Narayanan, Diego A Vicente, Yujia Liu, Jason P LaPorte, Bryan F Cox

Surgery· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition.
Chandra C Ghosh, Kara R Heatherton, Kyle P O' Connell, Ian S Alexander, Deborah A Greer, Bryan F Cox

Cancer Gene Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model.
Louis F Chai, John C Hardaway, Kara R Heatherton, Kyle P O'Connell, Jason P LaPorte, Bryan F Cox

J Surg Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity.
Louis F Chai, John C Hardaway, Kara R Heatherton, Kyle P O'Connell, Mikayla C Lopes, Bryan F Cox

Vaccines (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Jayanth S Shankara Narayanan, Diego A Vicente, Partha Ray, Louis F Chai, Suna Erdem, Bryan F Cox

Surgery· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models.
Marcin Klapczynski, Gerard D Gagne, Sherry J Morgan, Kelly J Larson, Bruce E Leroy, Bryan F Cox

J Pathol Inform· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Yanping Luo, Fang Jiang, Todd B Cole, Vincent P Hradil, David Reuter, Bryan F Cox

Cancer Chemother Pharmacol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.
Xiaoqin Liu, James T Limberis, Zhi Su, Kathryn Houseman, Gilbert J Diaz, Bryan F Cox

Life Sci· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.
Jonathon R Green, Gilbert J Diaz, James T Limberis, Kathryn A Houseman, Zhi Su, Bryan F Cox

J Pharmacol Toxicol Methods· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.
Vince S C Yeh, David W A Beno, Sevan Brodjian, Michael E Brune, Steven C Cullen, Bryan F Cox

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capsaicin-induced inhibition of platelet aggregation is not mediated by transient receptor potential vanilloid type 1.
Scott W Mittelstadt, Richard A Nelson, Jerome F Daanen, Andrew J King, Michael E Kort, Bryan F Cox

Blood Coagul Fibrinolysis· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors.
Zhi Su, Lee Preusser, Gilbert Diaz, Jonathon Green, Xiaoqin Liu, Bryan F Cox

Curr Drug Saf· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
Feng Luo, Nathan R Rustay, Terese Seifert, Beate Roesner, Vincent Hradil, Bryan F Cox

J Pharmacol Exp Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current.
Zhi Su, Deborah L Widomski, Xiaoqin Liu, James T Limberis, Jonathon Green, Bryan F Cox

Biochem Pharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
Andrew J King, Jason A Segreti, Kelly J Larson, Andrew J Souers, Philip R Kym, Bryan F Cox

Eur J Pharmacol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-selective antivascular effects of the novel anti-mitotic compound A-318315: An in vivo rat regional haemodynamic study.
Jason A Segreti, Kristin A Brooks, Kennan C Marsh, Joy L Bauch, Yan Lan, Bryan F Cox

Clin Exp Pharmacol Physiol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs.
James S Polakowski, Andrew J King, Thomas J Campbell, Richard A Nelson, Lee C Preusser, Bryan F Cox

J Cardiovasc Pharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational neuroimaging of the CNS: novel pathways to drug development.
Gerard B Fox, Chih-Liang Chin, Feng Luo, Mark Day, Bryan F Cox

Mol Interv· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.
Andrew J King, Jason A Segreti, Kelly J Larson, Andrew J Souers, Philip R Kym, Bryan F Cox

J Pharmacol Exp Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.
Yanping Luo, Vincent P Hradil, David J Frost, Saul H Rosenberg, Gary B Gordon, Bryan F Cox

Anticancer Drugs· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrophysiologic characterization of a novel hERG channel activator.
Zhi Su, James Limberis, Andrew Souers, Philip Kym, Ann Mikhail, Bryan F Cox

Biochem Pharmacol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis